Artiva Biotherapeutics
ARTV
34 hedge funds and large institutions have $72.7M invested in Artiva Biotherapeutics in 2025 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 15 reducing their positions, and 12 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
40% more capital invested
Capital invested by funds: $52.1M → $72.7M (+$20.6M)
5.24% less ownership
Funds ownership: 74.32% → 69.08% (-5.2%)
15% less funds holding
Funds holding: 40 → 34 (-6)
50% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 12
73% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 15
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Two Sigma Investments
New York
|
+$470K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$328K |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$300K |
| 4 |
Jane Street
New York
|
+$154K |
| 5 |
Renaissance Technologies
New York
|
+$140K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$2.29M |
| 2 |
VP
venBio Partners
San Francisco,
California
|
-$1.89M |
| 3 |
BNP Paribas Financial Markets
Paris,
France
|
-$446K |
| 4 |
BlackRock
New York
|
-$309K |
| 5 |
Citigroup
New York
|
-$303K |
ARTV Hedge Fund Activity: Q4 2025 in Review
34 of the 8,275 institutional investors tracked by Wall St. Rank reported a position in Artiva Biotherapeutics (ARTV) for Q4 2025, worth a combined $72.7M — up 40% from $52.1M a quarter earlier.
Sellers outnumbered buyers: 12 funds closed out of ARTV and 6 opened new positions — a net loss of 6 holders — while 15 trimmed existing stakes and 4 added.
The largest buyer was Two Sigma Investments, adding an estimated $470K. The largest seller was Citadel Advisors, exiting entirely with an estimated $2.29M sold.
- 34 institutional investors held Artiva Biotherapeutics (ARTV) as of Q4 2025, down from 40 in Q3 2025.
- Funds reported $72.7M of Artiva Biotherapeutics stock for Q4 2025, up 40% quarter-over-quarter.
- 6 funds opened new Artiva Biotherapeutics positions in Q4 2025 and 12 closed out, a net change of -6 holders.
- The largest Artiva Biotherapeutics buyer in Q4 2025 was Two Sigma Investments, an estimated $470K added.
- The largest Artiva Biotherapeutics seller in Q4 2025 was Citadel Advisors, an estimated $2.29M sold.
Based on aggregated 13F filings for Q4 2025.